Market News & Trends
Asahi Kasei Develops Novel Membrane System to Dehydrate Organic Solvents Without Heat or Pressure - Contributing to Process Optimization in the Pharmaceutical Industry
Asahi Kasei has developed a novel membrane system for dehydrating organic solvents for pharmaceutical applications without the application of heat or pressure. This system can…
Roche Completes Acquisition of Telavant From Roivant, Including Rights to Novel TL1A Directed Antibody for Inflammatory Bowel Disease Treatment
Roivant recently announced the completion of the previously announced acquisition by Roche of Telavant, for an upfront payment of approximately $7.1 billion…..
Aeterna Zentaris & Ceapro Announce Merger to Create Diversified Biopharmaceutical Company
Aeterna Zentaris Inc. and Ceapro Inc. recently announced they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction…..
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
Rani Therapeutics Holdings, Inc. recently announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill…
Aptamer Group Signs Material Agreement With Genetic Medicines Company
Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, recently announces it has entered into a material…
Clene Announces Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. recently announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8, the…
ReciBioPharm Partners With Acuitas Therapeutics to Provide Rapid Technology Transfers & cGMP Manufacture of LNP Formulations
ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, and biotechnology firm Acuitas Therapeutics have recently announced they are taking their partnership to the next level….
Athira Pharma Announces Encouraging Results From SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia & Dementia With Lewy Bodies
Athira Pharma, Inc. recently announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia…
ADMA Biologics Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age & Older
ADMA Biologics, Inc. recently announced the US FDA has approved the company’s supplemental Biologics License Application submitted under section 351(a) of the Public Health Service…
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation recently announced the US FDA has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate…
Abzena Partners With ProteoNic to Offer Enhanced CHO Cell Line
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO, recently announced a partnership with ProteoNic Biosciences BV to license their premium protein expression….
Coya Therapeutics & Dr. Reddy’s Laboratories Enter Development & Commercialization Agreement for ALS Treatment
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. recently announced they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for….
AbbVie Announces FDA & EMA Updates for Epcoritamab for the Treatment of Relapsed/Refractory Follicular Lymphoma
AbbVie recently announced updates from the US FDA and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed…
Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 & ELAINE-2 Trial Results
Sermonix Pharmaceuticals Inc. recently announced results of its two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies were published in Annals of Oncology,…
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control & Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells
Sana Biotechnology, Inc. recently announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP)…
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial
TILT Biotherapeutics recently presented safety and efficacy data from its international Phase 1 trial in patients with metastatic melanoma (NTC04217473), in an oral presentation at…
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen & Ultevursen Ophthalmic Assets
Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU….
Rigel Pharmaceuticals & MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML & Other Cancers
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center (MD Anderson) recently announced a multi-year strategic development collaboration to expand the evaluation…
IMIDomics & Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research & Development
IMIDomics recently announced it is expanding its strategic collaboration with Bristol Myers Squibb that extends the existing relationship between the two companies, advancing their shared commitment to….
